Table 1

Patient characteristics at enrollment

CharacteristicsNo. of patients (%)P
SVILE (n = 52)P-GemOx (n = 51)
Male34 (65.4)34 (66.7)0.891
Age, median (range, years)46 (18–63)47 (18–67)0.368
B-symptoms present41 (78.8)33 (64.7)0.111
†PET/CT at diagnosis51 (98.1)a51 (100)1.000
‡SUVmax, mean ± SD11.727 ± 5.94513.747 ± 7.2320.117
Lymph node involvement18 (34.6)15 (29.4)0.571
Nasal involvement52 (100)50 (98.0)a0.495
Decreased serum album19 (36.5)13 (25.5)0.226
Elevated serum §LDH12 (23.1)13 (25.5)0.775
Elevated serum β-2 MG28 (53.8)24 (47.1)0.491
Ann Arbor stage
I/II36 (69.2)33 (64.7)0.625
III/IV16 (30.8)18 (35.3)
PINK grade
Low25 (48.1)24 (47.1)0.258
Intermediate18 (34.6)12 (23.5)
High9 (17.3)15 (29.4)
¥-IFRT45 (86.5)46 (90.2)0.563

†PET/CT, positron emission tomography/computed tomography; ‡SUV, standard uptake value; §LDH, lactate dehydrogenase; β2 MG, beta-2 microglobulin; ¥-IFRT, involved-field radiotherapy; aFisher test was used when n < 5.